VERA

Vera Therapeutics, Inc. Class A · NASDAQ

Sector Health Technology
Industry Biotechnology
Website veratx.com
Employees(FY) 49
ISIN US92337R1014

Performance

-5.75%

+11.15%

+16.12%

+10.53%

+197.46%

YTD

+238.89%

Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Advanced Technical Analysis

Technical Analysis of VERA 2024-11-20

The Moving Average Score of 76 indicates a strong bullish sentiment, while the Oscillators Score of 36 suggests bearish pressure, and the Technical Score of 56 reflects a neutral stance. Overall, the mixed signals imply a cautious bullish outlook, with the moving averages supporting upward momentum despite the bearish oscillators.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of VERA

Stock Rank

Recent News & Updates

2024-11-18 08:00
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer(GlobeNewswire)
2024-11-17 19:00
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer(Globenewswire)
2024-11-11 16:05
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-11-11 09:55
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet(Zacks)
2024-11-11 08:00
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study(GlobeNewswire)
2024-11-11 03:05
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-11-10 19:00
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study(Globenewswire)
2024-11-08 16:05
Vera Therapeutics to Participate at Upcoming Investor Conferences(GlobeNewswire)
2024-11-08 07:11
Wedbush Raises Vera Therapeutics' Price Target to $38 From $30, Maintains Neutral rating(MT Newswires)
2024-11-08 03:05
Vera Therapeutics to Participate at Upcoming Investor Conferences(Globenewswire)
2024-11-07 19:00
Vera Therapeutics to Participate at Upcoming Investor Conferences(Globenewswire)
2024-11-07 13:38
Vera Therapeutics Shares Rise After Q3 Results(MT Newswires)
2024-11-07 08:00
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results(GlobeNewswire)
2024-11-06 19:00
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-10-29 20:21
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock(GlobeNewswire)
2024-10-29 08:21
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock(Globenewswire)
2024-10-28 21:25
Vera Therapeutics price target raised to $64 from $56 at Guggenheim(Yahoo Finance)
2024-10-28 17:43
Vera Therapeutics Breaks Out On Promising Results For Kidney Drug(Investor's Business Daily)
2024-10-28 17:37
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock(GlobeNewswire)
2024-10-28 11:55
Vera Therapeutics Shares Jump After Supportive Data From Phase 2b Trial of Kidney Disease Drug Candidate(MT Newswires)
2024-10-28 10:33
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years(Benzinga)
2024-10-28 05:37
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock(Globenewswire)
2024-10-27 22:13
Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug(Yahoo Finance)
2024-10-26 19:30
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024(GlobeNewswire)
2024-10-26 07:30
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024(Globenewswire)
2024-10-16 08:23
Scotiabank Initiates Vera Therapeutics at Sector Outperform(MT Newswires)
2024-10-04 16:05
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-10-04 04:05
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-10-02 07:08
Vera Therapeutics Expands Development of Kidney Disease Drug Pipeline(MT Newswires)
2024-10-02 06:30
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases(GlobeNewswire)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.